These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30280369)

  • 1. Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival.
    England BR; Sayles H; Michaud K; Thiele GM; Poole JA; Caplan L; Sauer BC; Cannon GW; Reimold A; Kerr GS; Baker JF; Mikuls TR
    Clin Rheumatol; 2018 Nov; 37(11):2907-2915. PubMed ID: 30280369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry.
    Mikuls TR; Fay BT; Michaud K; Sayles H; Thiele GM; Caplan L; Johnson D; Richards JS; Kerr GS; Cannon GW; Reimold A
    Rheumatology (Oxford); 2011 Jan; 50(1):101-9. PubMed ID: 20659916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.
    Sparks JA; He X; Huang J; Fletcher EA; Zaccardelli A; Friedlander HM; Gill RR; Hatabu H; Nishino M; Murphy DJ; Iannaccone CK; Mahmoud TG; Frits ML; Lu B; Rosas IO; Dellaripa PF; Weinblatt ME; Karlson EW; Shadick NA; Doyle TJ
    Arthritis Rheumatol; 2019 Sep; 71(9):1472-1482. PubMed ID: 30951251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.
    Cannon GW; Mikuls TR; Hayden CL; Ying J; Curtis JR; Reimold AM; Caplan L; Kerr GS; Richards JS; Johnson DS; Sauer BC
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1680-90. PubMed ID: 21905260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis.
    England BR; Sayles H; Michaud K; Caplan L; Davis LA; Cannon GW; Sauer BC; Solow EB; Reimold AM; Kerr GS; Schwab P; Baker JF; Mikuls TR
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):36-45. PubMed ID: 26097231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.
    Davis LA; Cannon GW; Pointer LF; Haverhals LM; Wolff RK; Mikuls TR; Reimold AM; Kerr GS; Richards JS; Johnson DS; Valuck R; Prochazka A; Caplan L
    J Rheumatol; 2013 Jun; 40(6):809-17. PubMed ID: 23547211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
    Rojas-Serrano J; Herrera-Bringas D; Pérez-Román DI; Pérez-Dorame R; Mateos-Toledo H; Mejía M
    Clin Rheumatol; 2017 Jul; 36(7):1493-1500. PubMed ID: 28585060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: insights from the KOBIO Registry.
    Kim JW; Shin K; Jung J; Suh CH; Kim J; Lee SK; Kim HA
    Clin Exp Rheumatol; 2024 Sep; 42(9):1781-1791. PubMed ID: 38634363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease.
    Brooks R; Baker JF; Yang Y; Roul P; Kerr GS; Reimold AM; Kunkel G; Wysham KD; Singh N; Lazaro D; Monach PA; Poole JA; Ascherman DP; Mikuls TR; England BR
    Rheumatology (Oxford); 2022 Nov; 61(12):4667-4677. PubMed ID: 35377443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
    Kiely P; Busby AD; Nikiphorou E; Sullivan K; Walsh DA; Creamer P; Dixey J; Young A
    BMJ Open; 2019 May; 9(5):e028466. PubMed ID: 31061059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Depression and Disease Activity in United States Veterans With Early Rheumatoid Arthritis Receiving Methotrexate.
    Rathbun AM; England BR; Mikuls TR; Ryan AS; Barton JL; Shardell MD; Hochberg MC
    J Rheumatol; 2021 Jun; 48(6):813-820. PubMed ID: 33191277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
    Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
    Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
    Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of serum cytokines and chemokines with the risk of incident cancer in a prospective rheumatoid arthritis cohort.
    England BR; Campany M; Sayles H; Roul P; Yang Y; Ganti AK; Sokolove J; Robinson WH; Reimold AM; Kerr GS; Cannon GW; Sauer BC; Baker JF; Thiele GM; Mikuls TR
    Int Immunopharmacol; 2021 Aug; 97():107719. PubMed ID: 33933845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands.
    Matthijssen XME; Niemantsverdriet E; Huizinga TWJ; van der Helm-van Mil AHM
    PLoS Med; 2020 Sep; 17(9):e1003296. PubMed ID: 32960885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
    Johnson TM; Sayles HR; Baker JF; George MD; Roul P; Zheng C; Sauer B; Liao KP; Anderson DR; Mikuls TR; England BR
    Ann Rheum Dis; 2021 Nov; 80(11):1385-1392. PubMed ID: 34049859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
    Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
    Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems.
    Kerr GS; Swearingen C; Mikuls TR; Yazici Y
    J Clin Rheumatol; 2017 Jan; 23(1):12-18. PubMed ID: 28002151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.